Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

This small biotech could be the biggest winner of all if its COVID-19 vaccine performs well in late-stage testing.

How Novavax Is Keeping Up With the Big Players in the Coronavirus Vaccine Race

Novavax, Inc. (NVZAX) Management Presents at H.C.

AstraZeneca

CureVac B.V

GlaxoSmithKline

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Whether or not we get an 'October Surprise' from President Donald Trump, these coronavirus vaccine stocks look hot now. 
AstraZeneca (NYSE:AZN)
CureVac (NASDAQ:CVAC)
GlaxoSmithKline (NYSE:GSK)
Inovio (NASDAQ:INO)
Johnson & Johnson (NYSE:JNJ)
Moderna (NASDAQ:MRNA)
Novavax (NASDAQ:NVAX)
The post 7 Coronavirus Vaccine Stocks to Watch as Approval Nears appeared first on InvestorPlace.

7 Coronavirus Vaccine Stocks to Watch as Approval Nears

Novavax is likely to recover with its vaccine results. If successful, I think its vaccine will make NVAX stock worth at least $229.

Novavax Stock Has a Clear Path to Over $200

Novavax signed an agreement with the Canadian government for its potential Covid-19 vaccine Aug. 31. NVAX stock has been falling ever since.

Novavax’s Run to $200 by the End of 2020 Is Looking Less Likely 

While factors could change the game, you can't say it's over for NVAX stock. Still, wait for lower prices before diving into high-risk, high-return Novavax.

It’s Not Over Yet for Novavax Stock, but Wait for Another Pullback

BioNTech SE

Pfizer

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

Merck

Companies could only distribute the vaccine internationally if domestic need is met.

Senate Considers Bill to Block International Distribution of Coronavirus Vaccine

AstraZeneca's pause in key Covid vaccine testing, after a participant fell ill, boosted shares of rival vaccine makers Moderna and Novavax for a second day amid the push to end the pandemic.
The post Covid Report: AstraZeneca Fallout Continues To Propel Moderna, Novavax Stock appeared first on Investor's Business Daily.

Covid Report: AstraZeneca Fallout Continues To Propel Moderna, Novavax Stock

Reality Check For COVID Vaccines: Caution Moderna, BioNTech, Novavax

GAITHERSBURG, Md., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will participate in five upcoming investor conferences. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.

Novavax to Participate in Upcoming Investor Conferences

Novavax isn't the closest to the finish line of the coronavirus vaccine race. But the company could still end up a winner.

Is Novavax a Buy Before Nov. 3?

This clinical-stage biotech stock appears to be an attractive pick for aggressive investors after its recent pullback.

3 Compelling Reasons to Buy Novavax Right Now

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?

Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

Sanofi

These healthcare companies have had plenty of help in building the manufacturing capacity needed to produce billions of vaccine doses.

6 Companies Racing to Mass-Produce a Coronavirus Vaccine in 2021

NVAX stock is a binary trade because they are trying to make sure this time is different. Novavax can be a risky trade, but profitable.

Confidence Is Essential for Novavax Stock Investors

The race for finding the COVID-19 vaccine is in full swing, and it has just seen one team move ahead of the others.

What Does a Perfect COVID-19 Vaccine Actually Mean?

Dynavax Technologies

Even these top contenders had a rough end to the summer.

Why These 3 Coronavirus Vaccine Stocks Plunged in August

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Implied Volatility Surging for Novavax (NVAX) Stock Options

NVAX stock is up over 2,000% since March. But as the clinical trials advance, investors need to decide if they're in or out.

This Is No Time to Lack Conviction on Novavax

Novavax had a good run in the last few months and after the August drop, investors will look forward to the clinical study numbers
The post When It Comes to Novavax Stock, It’s All About Clinical Results appeared first on InvestorPlace.
More From InvestorPlace
		
					
				
					Why Everyone Is Investing in 5G All WRONG				
			
					
				
					America’s #1 Stock Picker Reveals His Next 1,000% Winner				
			
					
				
					Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company				
			
					
				
					Radical New Battery Could Dismantle Oil Markets

When It Comes to Novavax Stock, It’s All About Clinical Results

Nine leading U.S. and European vaccine developers pledged to uphold the scientific standards that their experimental immunizations will be held against, amid a hurried global race to contain the pandemic.

Nine biopharma CEOs pledge to make safety the main focus in coronavirus vaccine development

Altimmune

Vaxart

How to Invest in Coronavirus Vaccine Stocks

Block

Tesla

Or are their stock prices likely to fall?

News for Novavax Stock (NVAX)